A549-ACE2 SARS-CoV-1 antiviral effect screening assay v1

To evaluate the antiviral efficacy of compounds against SARS-CoV-1 infection using an engineered A549-ACE2 cell line model. A549 human lung adenocarcinoma cells stably transfected to express ACE2 receptors were used as the host cell system. Cells were pre-treated with a range of test compounds prior to SARS-CoV-1 infection at a multiplicity of infection levels. The regular P-GP inhibitor used was Elacridar and positive control was Remdesivir Viral replication was assessed at post-infection using detection methods. Control compounds/vehicle controls were included for comparison.